Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
On June 24, 2025, Syndax Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the supplemental New Drug Application (sNDA) for ···【more】
Article source：Captain MedicineRelease date：2026-01-28Recommended：93
Acute lymphoblastic leukemia (ALL) is a hematologic malignancy originating from B-lineage or T-lineage lymphoid cells. Most adult ALL cases have an acute onset, with fever, bleedin···【more】
Article source：Captain MedicineRelease date：2026-01-28Recommended：74
Recently, Syndax Pharmaceuticals announced additional positive data from the AUGMENT-101 trial of Revuforj (revumenib) in patients with relapsed or refractory (R/R) nucleophosmin 1···【more】
Article source：Captain MedicineRelease date：2026-01-28Recommended：73
Lorlatinib is a third-generation ALK/ROS1 tyrosine kinase inhibitor, primarily indicated for the treatment of ALK-positive or ROS1-positive advanced non-small cell lung cancer (NSC···【more】
Article source：Captain MedicineRelease date：2026-01-27Recommended：87
Lorlatinib is a third-generation targeted therapy indicated for ALK-positive metastatic non-small cell lung cancer (NSCLC), primarily used in patients who have developed resistance···【more】
Article source：Captain MedicineRelease date：2026-01-26Recommended：66
Concurrent use of this medicine with any of the following medications is generally not recommended, but may be necessary in certain circumstances. If both medications are prescribe···【more】
Article source：Captain MedicineRelease date：2026-01-26Recommended：99
While certain medications should not be used together at all, in other cases, it may be necessary to use two different drugs simultaneously even if an interaction might occur.What ···【more】
Article source：Captain MedicineRelease date：2026-01-26Recommended：88
While exerting the intended therapeutic effects, a medication may also induce certain adverse reactions. Although not all side effects will occur, medical attention may be required···【more】
Article source：Captain MedicineRelease date：2026-01-26Recommended：93
In addition to the intended effects, medications may cause some adverse reactions. Although not all of these side effects may occur, medical attention may be required if they do ap···【more】
Article source：Captain MedicineRelease date：2026-01-26Recommended：87
Lorlatinib is an antineoplastic (anticancer) medication. It interferes with the growth of cancer cells, which are eventually eliminated by the body. This medicine is available only···【more】
Article source：Captain MedicineRelease date：2026-01-26Recommended：88
Lorlatinib is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) harboring specific types of anaplastic lymphoma kinase (ALK) gene abnormali···【more】
Article source：Captain MedicineRelease date：2026-01-26Recommended：100
Lorlatinib is a targeted therapy indicated for the treatment of ALK-positive non-small cell lung cancer (NSCLC). Its dietary restrictions primarily aim to avoid foods that may inte···【more】
Article source：Captain MedicineRelease date：2026-01-26Recommended：104
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：2272025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：4532024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：2332025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：2462025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：2262025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：2552025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：2352025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：2172025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
